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a host factor to link two bacterial proteins is
a striking example of bacterial intimacy
with the host.
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Successful viruses must overcome the body’s immune defenses. In this issue ofCell Host &Microbe, Goffinet
et al. (2009) provide evidence that the host protein CD317, the target of the HIV Vpu protein, is part of an
ancient innate immune response directed against budding viruses.The human immunodeficiency virus (HIV) is
a lentivirus that expresses a small comple-
ment of so-called accessory proteins.
These proteins—Vif, Vpr, Vpu, and Nef—
have been termed ‘‘accessory’’ because
they are not required for the nuts and bolts
of virus particle construction but are
needed for a productive infection in the
host. Thus, these proteins are good candi-
dates for factors thatare necessary toover-
come host defenses.
Indeed, examination of how accessory
proteins function has revealed some of
the immune defenses the virus must
combat to establish a persistent infection.
Intriguingly, theaccessory proteinsall func-
tion to degrade host proteins that would
otherwise serve protective functions. The
Nef protein targets and degrades the major
histocompatibility class I molecules HLA-A
and -B in lysosomal compartments to
evade recognition by cytotoxic T lympho-
cytes (Roeth et al., 2004). The Vif protein
targets and destroys members of the
APOBEC family of proteins thatdisrupt viral
genome synthesis by cytidine deamination
and subsequent viral genome degradation
(reviewed in Malim and Emerman, 2008).Vpr remains somewhat mysterious, but
it’s known to associate with degradative
machinery that targets an as-yet-unchar-
acterized factor, possibly the cellular
protein, UNG, that plays a role in the
DNA-damage response (Schrofelbauer
et al., 2007). Vpu degrades the viral
receptor, CD4, to prevent superinfection
of already-infected cells and to decrease
detrimental envelope-CD4 interactions
within the infected cell (Figure 1). Addition-
ally, in this issue of Cell Host & Microbe,
Goffinet and colleagues provide evidence
that Vpu degrades CD317 (also known as
tetherin/BST-2/HM1.24) to reverse the
antiviral effects of this protein (Goffinet
et al., 2009). The nature of the inhibitory
effect of CD317 on viral infection remains
unclear, but it targets a very late stage of
viral budding and leads to tethering of viral
particles to the infected cell surface. Inter-
estingly, the particles can be released by
protease digestion indicating that budding
particles are linked to the cell surface via
a protein tether (Figure 1) (Neil et al., 2007).
CD317 was previously identified as
a target of both the Kaposi’s sarcoma
herpes virus (KSHV) K5 protein and theCell Host & MicrobeHIV Vpu protein (Bartee et al., 2006). Tar-
geting of this protein by two unrelated
viruses strongly suggested an important
but nonspecific antiviral effect. Subse-
quent studies revealed that CD317 is an
interferon alpha-inducible factor that
inhibited HIV budding, unless Vpu was
expressed (Neil et al., 2008). Vpu was
found to alter CD317 surface expression
and intracellular localization in some
studies (Van Damme et al., 2008), but not
in others (Neil et al., 2008), and this effect
of Vpu appears to vary with the cell type
used (Miyagi et al., 2009). Because Goffi-
net et al. (2009) demonstrate that the ratio
of Vpu to CD317 is important for activity,
different results may stem from differ-
ences in expression level of these two
factors. Alternatively, or in addition, the
relative expression of other Vpu targets
may impact the observed phenotype.
In this issue ofCell Host &Microbe, Gof-
finet and colleagues demonstrate that
human Vpu markedly decreases the half-
lifeofhumanCD317 in293cellsexpressing
ectopic, HA-tagged CD317 and inhibitors
of the proteasome reverse that degrada-
tion. Notably, these inhibitors also5, March 19, 2009 ª2009 Elsevier Inc. 217
Cell Host & Microbe
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the antiviral activity of CD317. Moreover,
Goffinet and colleagues confirmed prior
reports (Van Damme et al., 2008) that the
effect of Vpu on CD317 requires key serine
residues in the cytoplasmic tail of Vpu.
These requirements are similar to those
needed for Vpu to degrade CD4. The
serine residues in the cytoplasmic tail of
Vpu allow it to interact with a beta transdu-
cin repeat containing protein (bTrCP),
which is a component of an ubiquitin
ligase complex. Vpu is thought to simulta-
neously bind both CD4 and bTrCP to
promote the ubiquitination, cytosolic
translocation, and proteasomal degrada-
tion of CD4 (reviewed in Malim and Emer-
man, 2008). Importantly, there are also
clear differences between Vpu’s effects
on CD317 and CD4. The transmembrane
domain of Vpu is dispensable for CD4
degradation, whereas this domain is
required for Vpu to colocalize with
CD317 and to counteract its inhibitory
effects (Neil et al., 2008). Thus, the trans-
membrane domain may be needed for
CD317 to interact directly or indirectly
with Vpu.
CD317 has a very unusual topology in
that it has an N-terminal transmembrane
domainaswell asaglycosylphosphatidyli-
nositol (GPI) anchor that can link its
C-terminal domain with another region of
the membrane. This structural character-
istic has led to the interesting model that
CD317 links the cellular membrane to the
budding viral membrane, physically teth-
ering the viral protein to the cell (Neil
et al., 2008). Previous studies agree that
CD317 redistributes Gag from a punctate,
cytoplasmic distribution to striking aggre-
gations at membrane structures (Neil
et al., 2008; Van Damme et al., 2008).
However, Goffinet and colleagues now
demonstrate that colocalization of CD317
with Gag is not required for its antiviral
activity. Additionally, recent reports were
unable to detect CD317 on budded viral
particles removed from cells with physical
shearing (Miyagi et al., 2009). Thus, further
work is needed to clarify whether CD317
physically tethers viral buds to the cell or
whether it plays another, more indirect
role.
Goffinet and colleagues also demon-
strate that the antiviral effects of CD317
are conserved among mice, rats, and
humans. Remarkably, this functional
conservation occurs with only very limited
(41%–36%) sequence identity. Thus,
CD317 represents an ancient form of
immune defense that has been evolution-
arily conserved across species. This
conservation of function with remarkable
sequence divergence is most consistent
with a model in which CD317 has an indi-
rect effect on viral budding rather than
a specific interaction with the HIV Gag
protein. A nonspecific effect of CD317
on virus budding is also suggested by
prior results indicating that Vpu promotes
virus production from a wide array of
retroviruses, as well as filoviruses such
as Ebola and Marburg (Neil et al., 2007).
The degradation of CD317 by KSHV K5
also implies that CD317 acts as an inhib-
itor of this herpes virus (Bartee et al.,
2006).
Notably, Goffinet and colleagues
demonstrate that Vpu is not able to coun-
teract the effects of rodent CD317; rather,
it selectively targets the human form of
CD317. This result is not too surprising
given that Vpu was unable to inhibit inter-
feron alpha effects on virus production in
more closely related African green
monkey cells (Neil et al., 2007). Goffinet
and colleagues were not able to identify
a region of CD317 that conferred Vpu
sensitivity using rodent-human chimeras.
However, a recent study reports that
reciprocal exchange of transmembrane
domains between human and monkey
CD317 confers sensitivity and resistance
to Vpu. Thus, the transmembrane domain
appears to be the domain that determines
species-specific responsiveness to Vpu,
and thus, it may be the region through
which Vpu interacts, directly or indirectly
with CD317 (McNatt et al., 2009).
To complicate things further, another
cellular protein has been identified as
a Vpu target required for inhibition of
budding. This protein, calcium-modu-
lating cyclophilin ligand (CAML), was iso-
lated as a Vpu-binding protein in a yeast
two-hybrid screen (Varthakavi et al.,
2008). It will be important to determine
whether CAML and CD317 are both
needed for the same pathway or whether
one protein affects the stability or intracel-
lular localization of the other.
For the establishment of a persistent
infection, viruses must evolve ways to
neutralize the most important compo-
nents of the host immune response. The
recent progress in identifying Vpu targets
is a major step forward in understanding
the immunoevasive tactics of HIV.
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